专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007079592A1 PROTEIN C PATHWAY ASSOCIATED POLYMORPHISMS AS RESPONSE PREDICTORS TO ACTIVATED PROTEIN C OR PROTEIN C LIKE COMPOUND ADMINISTRATION 审中-公开
标题翻译：蛋白C途径相关多态性作为反应蛋白C或蛋白C的化合物类似化合物的施用
公开(公告)号：WO2007079592A1
公开(公告)日：2007-07-19
申请号：PCT/CA2007/000054
申请日：2007-01-12
申请人： THE UNIVERSITY OF BRITISH COLUMBIA , RUSSELL, James, A. , WALLEY, Keith, R.
发明人： RUSSELL, James, A. , WALLEY, Keith, R.
IPC分类号： C40B40/06 , A61K38/36 , A61K38/48 , A61P29/00 , A61P31/00 , A61P7/02 , C07H21/04 , C12Q1/00 , C12Q1/68 , C07K14/47 , C07K14/745 , C12N15/12 , C12N15/57 , C12N9/64
CPC分类号： A61K38/4866 , C12N9/6464 , C12Q1/6883 , C12Q2600/106 , C12Q2600/156 , C12Q2600/172 , C12Y304/21069 , Y02A50/385 , Y02A50/401 , Y02A50/409 , Y02A50/411 , Y02A50/473 , Y02A50/478 , Y10T436/143333
摘要： The invention provides methods, nucleic acids, compositions and kits for predicting a subject's response to treatment with activated protein C or protein C like compound to identify subjects having a greater benefit from treatment with activated protein C. The method generally comprises determining a protein C pathway associated gene polymorphism genotype(s) of a subject for one or more polymorphisms in the these genes, comparing the determined genotype with known genotypes for the polymorphism that correspond with an improved response polymorphism to identify potential subjects having an inflammatory condition who are more likely to benefit from treatment with activated protein C or protein C like compound and subsequent to treatment recover from the inflammatory condition. The invention also provides for methods of treating such subjects with an anti-inflammatory agent or anti-coagulant agent based on the subject's genotype.
摘要翻译：本发明提供了用于预测受试者对用活化蛋白C或蛋白C类化合物治疗的反应的方法，核酸，组合物和试剂盒，以鉴定受活化蛋白C治疗具有更大益处的受试者。该方法通常包括测定蛋白C途径将这些基因中的一个或多个多态性的受试者的相关基因多态性基因型进行比较，将确定的基因型与已知基因型进行比较，所述多态性与改善的应答多态性相对应，以鉴定具有更可能发生炎症的潜在受试者受益于用活化蛋白C或蛋白C类化合物治疗，随后治疗从炎症状态恢复。本发明还提供了基于受试者的基因型用抗炎剂或抗凝血剂治疗这些受试者的方法。

2. 发明申请

WO2006136033A1 COAGULATION FACTOR III POLYMORPHISMS ASSOCIATED WITH PREDICTION OF SUBJECT OUTCOME AND RESPONSE TO THERAPY 审中-公开
标题翻译：凝血因子III多态性与预测受试者的预后和治疗反应
公开(公告)号：WO2006136033A1
公开(公告)日：2006-12-28
申请号：PCT/CA2006/001058
申请日：2006-06-23
申请人： THE UNIVERSITY OF BRITISH COLUMBIA , RUSSELL, James, A. , WALLEY, Keith, R.
发明人： RUSSELL, James, A. , WALLEY, Keith, R.
IPC分类号： C12Q1/68 , A61K45/00 , A61P29/00 , A61P7/02 , C40B40/06 , G01N33/50 , C07H21/00 , C12N15/57
CPC分类号： C07K14/745 , C07K14/70596 , C12Q1/6883 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156 , C12Q2600/172
摘要： ABSTRACT The invention provides methods and kits for obtaining a prognosis for a subject having or at risk of developing an inflammatory condition or hypertension. The method generally comprises determining a coagulation factor III genotype(s) of a subject for one or more SNPs, comparing the determined genotype with known genotypes for the polymorphism that correspond with the ability of the subject to recover from the inflammatory condition and identifying subjects based on their prognosis. The invention also provides for methods of identifying potential subjects having an inflammatory condition who are more likely to benefit from treatment with an anti-inflammatory agent or anti-coagulant agent and subsequent to treatment recover from the inflammatory condition. The invention also provides for methods of treating such subjects with an anti-inflammatory agent or anti-coagulant agent based on the subject's genotype.
摘要翻译：摘要本发明提供了获得具有或有发展为炎性病症或高血压危险的受试者的预后的方法和试剂盒。该方法通常包括确定一个或多个SNP的受试者的凝血因子III基因型，将确定的基因型与已知基因型与多态性相对应，所述多态性与受试者从炎性病症恢复的能力相符合并鉴定受试者对他们的预后。本发明还提供了鉴定潜在受试者的方法，所述潜在受试者具有更可能受益于用抗炎剂或抗凝血剂治疗并且随后治疗从炎症状态恢复的炎性病症。本发明还提供了基于受试者的基因型用抗炎剂或抗凝血剂治疗这些受试者的方法。

3. 发明申请

WO2005085274A1 TOLL-LIKE RECEPTOR 2 (TLR-2) HAPLOTYPES PREDICT OUTCOME OF PATIENTS 审中-公开
标题翻译： TOLL-LIKE RECEPTOR 2（TLR-2）HAPLOTYPES PREDICT OUTCOME OF PATIENTS
公开(公告)号：WO2005085274A1
公开(公告)日：2005-09-15
申请号：PCT/CA2005/000357
申请日：2005-03-04
申请人： THE UNIVERSITY OF BRITISH COLUMBIA , RUSSELL, James, A. , WALLEY, Keith, R.
发明人： RUSSELL, James, A. , WALLEY, Keith, R.
IPC分类号： C07H21/00
CPC分类号： C12Q1/6883 , C12Q2600/118 , C12Q2600/156 , C12Q2600/172
摘要： The invention provides methods and kits for obtaining a prognosis for a subject having or at risk of developing an inflammatory condition and or a gram positive infection. The method generally includes determining a toll-like receptor 2 (TLR-2) risk genotype of a subject for one or more SNPs, comparing the determined genotype with known genotypes for the polymorphism that correspond with the ability of the subject to recover from the inflammatory condition and identifying subjects based on their prognosis.
摘要翻译：本发明提供用于获得具有或具有发展为炎性病症和/或革兰氏阳性感染风险的受试者的预后的方法和试剂盒。所述方法通常包括确定一个或多个SNP的受试者的toll样受体2（TLR-2）风险基因型，将确定的基因型与已知基因型与已知基因型的多态性相对应，所述多态性与受试者从炎症中恢复的能力相对应条件和根据其预后鉴定受试者。

4. 发明申请

WO2005085273A1 THROMBOMODULIN (THBD) HAPLOTYPES PREDICT OUTCOME OF PATIENTS 审中-公开
标题翻译：血小板计数（THBD）HAPLOTYPES预测患者的成果
公开(公告)号：WO2005085273A1
公开(公告)日：2005-09-15
申请号：PCT/CA2005/000356
申请日：2005-03-04
申请人： THE UNIVERSITY OF BRITISH COLUMBIA , RUSSELL, James, A. , WALLEY, Keith, R.
发明人： RUSSELL, James, A. , WALLEY, Keith, R.
IPC分类号： C07H21/00
CPC分类号： C12Q1/6883 , C12Q2600/118 , C12Q2600/156 , C12Q2600/172
摘要： The invention provides methods and kits for obtaining a prognosis for a subject having or at risk of developing an inflammatory condition. The method generally comprises determining a thrombomodulin genotype(s) of a subject for one or more SNPs, comparing the determined genotype with known genotypes for the polymorphism that correspond with the ability of the subject to recover from the inflammatory condition and identifying subjects based on their prognosis.
摘要翻译：本发明提供了用于获得具有或具有发展炎性病症风险的受试者的预后的方法和试剂盒。该方法通常包括确定一个或多个SNP的受试者的血栓调节蛋白基因型，将确定的基因型与已知基因型与多态性的已知基因型进行比较，所述基因型与受试者从炎性病症恢复的能力相对应，并基于它们鉴别受试者预后。

5. 发明申请

WO2009033282A8 MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 14 (MAP3K14) POLYMORPHISMS AS INDICATORS OF SUBJECT OUTCOME IN CRITICALLY ILL SUBJECTS 审中-公开
标题翻译：作为主要作用指标的重要蛋白激酶蛋白激酶激酶14（MAP3K14）多态性
公开(公告)号：WO2009033282A8
公开(公告)日：2010-07-15
申请号：PCT/CA2008001612
申请日：2008-09-10
申请人： UNIV BRITISH COLUMBIA , SIRIUS GENOMICS INC , WALLEY KEITH R , RUSSELL JAMES A , MOODER KAREN PATRICIA , SIDDIQUI ASIM SAROSH
发明人： WALLEY KEITH R , RUSSELL JAMES A , MOODER KAREN PATRICIA , SIDDIQUI ASIM SAROSH
IPC分类号： A61K39/395 , A61K31/573 , A61K38/17 , A61K45/00 , A61P29/00 , C07K14/525 , C07K14/715 , C12N9/12 , C12N15/54 , C12Q1/68
CPC分类号： A61K31/573 , A61K45/06 , C12N9/1205 , C12Q1/6883 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156 , C12Q2600/172 , A61K2300/00
摘要： The present application provides methods, uses, commercial packages, and kits for obtaining a prognosis for a subject having or at risk of developing an inflammatory condition and for identifying subjects having a greater benefit from treatment with an anti-inflammatory agent or an anti-coagulant agent. The method generally includes determining the genotype at position rs7222094 or a polymorphic site in linkage disequilibrium thereto for a subject for a polymorphisms in the these genes. The application also provides for methods of identifying potential subjects having an inflammatory condition who are more likely to benefit from treatment with an anti-inflammatory agent or anti-coagulant agent and to recover from the inflammatory condition. The invention also provides for methods of treating such subjects with an anti-inflammatory agent or anti-coagulant agent based on the subject's genotype.
摘要翻译：本申请提供了用于获得具有或具有发展炎性病症风险的受试者的预后的方法，用途，商业包装和试剂盒，并且用于鉴定具有抗炎剂或抗凝剂治疗更大益处的受试者剂。该方法通常包括确定rs7222094位置的基因型或连锁不平衡的多态性位点，用于受试者中这些基因的多态性。本申请还提供了鉴定具有炎症状况的潜在受试者的方法，所述炎症病症更可能受益于用抗炎剂或抗凝血剂治疗并从炎性病症中恢复。本发明还提供了基于受试者的基因型用抗炎剂或抗凝血剂治疗这些受试者的方法。

6. 发明申请

WO2003100090A2 PROTEIN C POLYMORPHISMS USEFUL AS AN INDICATOR OF PATIENT OUTCOME 审中-公开
标题翻译：蛋白C多态性作为患者观察指标有用
公开(公告)号：WO2003100090A2
公开(公告)日：2003-12-04
申请号：PCT/CA2003/000751
申请日：2003-05-28
申请人： THE UNIVERSITY OF BRITISH COLUMBIA , RUSSELL, James, A. , WALLEY, Keith, R.
发明人： RUSSELL, James, A. , WALLEY, Keith, R.
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/118 , C12Q2600/156
摘要： The invention provides methods and kits for obtaining a prognosis for a patient having or at risk of developing an inflammatory condition. The method generally comprises determining a protein C promoter genotype of a patient for a polymorphism in the protein C promoter region of the patient, comparing the determined genotype with known genotypes for the polymorphism that correspond with the ability of the patient to recover from the inflammatory condition and identifying patients based on their prognosis. The invention also provides for methods of identifying other polymorphisms that correspond with the ability of the patient to recover from the inflammatory condition.
摘要翻译：本发明提供了用于获得具有或具有发展炎性病症风险的患者的预后的方法和试剂盒。该方法通常包括确定患者的蛋白C启动子基因型，用于患者的蛋白C启动子区域中的多态性，将确定的基因型与已知基因型与多态性相比较，其与患者从炎性病症恢复的能力相对应并根据患者的预后鉴别患者。本发明还提供了鉴定与患者从炎性病症恢复的能力相对应的其他多态性的方法。

7. 发明申请

WO9914017A8 POWERED-OPERATED SCREWDRIVING DEVICE 审中-公开
标题翻译：动力驱动螺丝刀装置
公开(公告)号：WO9914017A8
公开(公告)日：1999-11-04
申请号：PCT/US9818904
申请日：1998-09-11
申请人： JALBERT DAVID B , BUZZEO DAVID J , RUSSELL JAMES A , HEWITT CHARLES W
发明人： JALBERT DAVID B , BUZZEO DAVID J , RUSSELL JAMES A , HEWITT CHARLES W
IPC分类号： B25B21/00 , B25B23/00 , B25B23/04 , B23B31/107 , B25B15/00 , B25F3/00 , F16B23/00
CPC分类号： B25B23/04 , B25B21/00 , B25B23/0035 , B25B23/045
摘要： The present invention is a power-operated screwdriving device (14) configured to be used with a rotary power source (12) and a supply of collated screws. The device (14) comprises a housing structure (16) and a feeding assembly (18) defines a drive track (232) carried by the housing (16) and providing a workpiece engaging surface (20). The drive track (232) is configured to receive a lead screw (398) from the supply. A rotatable screw engaging bit member (52) is constructed and arranged to be operatively connected to the rotary power source (12) such that the rotary power source (12) rotates the screw engaging bit member (52) during a screwdriving operation. The rotatable screw engaging bit member (52) is movable relative to the drive track and the workpiece engaging surface (20) such that, when the workpiece engaging surface (20) is engaged with the surface of the workpiece, rotation of the bit member (52) and relative movement between the bit member (52) and the drive track (232) drives the lead screw (398) into the workpiece during the screwdriving operation. Screw depth setting structure (60) is positioned and configured such that the feeding assembly engaging surface (74) engages the feeding assembly (18) to thereby limit the relative movement occurring between the screw engaging bit member (52) and the workpiece engaging surface (38) during the screwdriving operation. The workpiece engaging surface (38) and the rotatable screw engaging bit member (52) are constructed and arranged such that, when the feeding assembly (18) is engaged with the feeding assembly engaging surface (74), a distance between a screw engaging end portion (81) of the bit member (52) and the workpiece engaging surface (80) determines the depth to which the lead screw (398) will be driven relative to the surface of the workpiece during the screwdriving operation. A manually engageable screw depth adjusting member (64) is disposed exteriorly of the housing structure (16) and operatively connected to the screw depth setting structure (60). The screw depth adjusting member (64) is constructed and arranged such that manual operation thereof moves the screw depth setting structure (60) through a range of adjustable positions to thereby adjust the depth to which the lead screw (398) will be driven to the surface of the workpiece during the screwdriving operation.
摘要翻译：本发明是一种动力驱动的螺旋驱动装置（14），该驱动装置构造成与旋转动力源（12）和供应的对准螺钉一起使用。装置（14）包括壳体结构（16），并且供给组件（18）限定由壳体（16）承载并提供工件接合表面（20）的驱动轨道（232）。驱动轨道（232）构造成接收来自电源的导螺杆（398）。可旋转的螺钉啮合钻头构件（52）被构造和布置成可操作地连接到旋转动力源（12），使得旋转动力源（12）在螺钉驱动操作期间旋转螺钉啮合钻头构件（52）。可旋转的螺钉啮合钻头构件（52）可相对于驱动轨道和工件接合表面（20）移动，使得当工件接合表面（20）与工件的表面接合时，钻头构件（ 52），并且在螺钉驱动操作期间，钻头构件（52）和驱动轨道（232）之间的相对运动将丝杠（398）驱动到工件中。螺钉深度设定结构60被定位和构造成使得供给组件接合表面74与供给组件18接合，从而限制螺钉接合钻头构件52和工件接合表面52之间发生的相对运动。在螺丝起子操作过程中。工件接合表面（38）和可旋转的螺钉啮合钻头构件（52）被构造和布置成使得当进给组件（18）与进给组件啮合表面（74）啮合时，螺钉啮合端部件钻头构件52的部分81和工件接合表面80确定了在螺丝驱动操作期间导螺杆398相对于工件表面被驱动的深度。可手动接合的螺钉深度调节构件（64）布置在壳体结构（16）的外部并且可操作地连接到螺钉深度设定结构（60）。螺杆深度调节构件64被构造和布置成使得其手动操作使螺杆深度设定结构60移动一定范围的可调位置，从而调节螺杆398将被驱动到的深度螺丝拧紧过程中工件的表面。

8. 发明申请

WO2009089620A8 PROTEIN C RS2069915 AS A RESPONSE PREDICTOR TO SURVIVAL AND ADMINISTRATION OF ACTIVATED PROTEIN C OR PROTEIN C-LIKE COMPOUND 审中-公开
标题翻译：蛋白C RS2069915作为活化蛋白C或蛋白C类化合物的生存和施用的反应预测
公开(公告)号：WO2009089620A8
公开(公告)日：2012-04-26
申请号：PCT/CA2009000037
申请日：2009-01-15
申请人： UNIV BRITISH COLUMBIA , SIRIUS GENOMICS INC , WALLEY KEITH R , RUSSELL JAMES A , SIDDIQUI ASIM SAROSH , GORDON ANTHONY , WILLIAMS MARK D , MACIAS WILLIAM L , KIRKWOOD SANDRA CLOSE , LILLY CO ELI
发明人： WALLEY KEITH R , RUSSELL JAMES A , SIDDIQUI ASIM SAROSH , GORDON ANTHONY , WILLIAMS MARK D , MACIAS WILLIAM L , KIRKWOOD SANDRA CLOSE
IPC分类号： C40B40/06 , A61K38/48 , A61K45/00 , C07H21/00 , C12N9/64 , C12N15/57 , C12Q1/68 , C40B30/00 , G06F19/18 , G06F19/24
CPC分类号： A61K31/7088 , A61K38/4866 , A61K45/06 , C12Q1/6883 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156 , C12Q2600/172 , G06F19/18 , G06F19/24 , Y02A90/26 , A61K2300/00
摘要： Provided herein are methods, oligonucleotides and peptide nucleic acids, compositions and kits for predicting a subject's response to treatment with activated protein C or protein C-like compound or susceptibility to major organ dysfunction or susceptibility to an inflammatory condition. The method generally comprises determining a genotype of said subject at one or more of polymorphic sites in the subject's protein C gene selected from one or more of the following: rs20069915 and one or more polymorphism sites in linkage disequilibrium thereto, selected from one or more of the following: rs2069910; rs2069916; rs2069924; rs2069931; rsl799808; rs2069920; and rs6714364 and may further involve comparing the determined genotype with known genotypes for the polymorphism that correspond with an improved response to treatment with activated protein C or protein C-like compound or correspond to susceptibility to major organ dysfunction or susceptibility to an inflammatory condition. Also provided are methods of treating subjects with an anti-inflammatory agent or anti-coagulant agent based on the subject's genotype.
摘要翻译：本文提供的方法，寡核苷酸和肽核酸，组合物和试剂盒用于预测受试者对用活化蛋白C或蛋白质C样化合物治疗或对主要器官功能障碍或对炎性病症易感性的敏感性的反应。该方法通常包括在受试者的蛋白C基因中的一个或多个多态性位点确定所述受试者的基因型，所述多态性位点选自以下一个或多个：rs20069915和与其连锁不平衡的一个或多个多态性位点，其选自以下的一个或多个如下：rs2069910; rs2069916; rs2069924; rs2069931; rsl799808; rs2069920; 和rs6714364，并且可以进一步涉及将所确定的基因型与已知的多态性基因型进行比较，所述基因型对应于用活化的蛋白C或蛋白质C样化合物治疗的改善的应答，或对应于对主要器官功能障碍或对炎性病症的易感性的易感性。还提供了基于受试者的基因型用抗炎剂或抗凝血剂治疗受试者的方法。

9. 发明申请

WO2009089620A1 PROTEIN C RS2069915 AS A RESPONSE PREDICTOR TO SURVIVAL AND ADMINISTRATION OF ACTIVATED PROTEIN C OR PROTEIN C-LIKE COMPOUND 审中-公开
标题翻译：蛋白C RS2069915作为活化蛋白C或蛋白C类化合物的生存和施用的反应预测
公开(公告)号：WO2009089620A1
公开(公告)日：2009-07-23
申请号：PCT/CA2009/000037
申请日：2009-01-15
申请人： THE UNIVERSITYOF BRITISH COLUMBIA , SIRIUS GENOMICS INC. , ELI LILLY AND COMPANY , WALLEY, Keith R. , RUSSELL, James A. , SIDDIQUI, Asim Sarosh , GORDON, Anthony , WILLIAMS, Mark D. , MACIAS, William L. , KIRKWOOD, Sandra Close
发明人： WALLEY, Keith R. , RUSSELL, James A. , SIDDIQUI, Asim Sarosh , GORDON, Anthony , WILLIAMS, Mark D. , MACIAS, William L. , KIRKWOOD, Sandra Close
IPC分类号： C40B40/06 , A61K38/48 , A61K45/00 , C07H21/00 , C12Q1/68 , C40B30/00 , C12N9/64 , C12N15/57 , G06F19/00
CPC分类号： A61K31/7088 , A61K38/4866 , A61K45/06 , C12Q1/6883 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156 , C12Q2600/172 , G06F19/18 , G06F19/24 , Y02A50/385 , Y02A50/401 , Y02A50/409 , Y02A50/411 , Y02A50/473 , Y02A50/478 , Y02A90/26 , A61K2300/00
摘要： Provided herein are methods, oligonucleotides and peptide nucleic acids, compositions and kits for predicting a subject's response to treatment with activated protein C or protein C-like compound or susceptibility to major organ dysfunction or susceptibility to an inflammatory condition. The method generally comprises determining a genotype of said subject at one or more of polymorphic sites in the subject's protein C gene selected from one or more of the following: rs20069915 and one or more polymorphism sites in linkage disequilibrium thereto, selected from one or more of the following: rs2069910; rs2069916; rs2069924; rs2069931; rsl799808; rs2069920; and rs6714364 and may further involve comparing the determined genotype with known genotypes for the polymorphism that correspond with an improved response to treatment with activated protein C or protein C-like compound or correspond to susceptibility to major organ dysfunction or susceptibility to an inflammatory condition. Also provided are methods of treating subjects with an anti-inflammatory agent or anti-coagulant agent based on the subject's genotype.
摘要翻译：本文提供的方法，寡核苷酸和肽核酸，组合物和试剂盒用于预测受试者对用活化蛋白C或蛋白质C样化合物治疗或对主要器官功能障碍或对炎性病症易感性的敏感性的反应。该方法通常包括在受试者的蛋白C基因中的一个或多个多态性位点确定所述受试者的基因型，所述多态性位点选自以下一个或多个：rs20069915和与其连锁不平衡的一个或多个多态性位点，其选自以下的一个或多个如下：rs2069910; rs2069916; rs2069924; rs2069931; rsl799808; rs2069920; 和rs6714364，并且可以进一步涉及将所确定的基因型与已知的多态性基因型进行比较，所述基因型对应于用活化的蛋白C或蛋白质C样化合物治疗的改善的应答，或对应于对主要器官功能障碍或对炎性病症的易感性的易感性。还提供了基于受试者的基因型用抗炎剂或抗凝血剂治疗受试者的方法。

10. 发明申请

WO2007140625A1 INTERFERON GAMMA POLYMORPHISMS AS INDICATORS OF SUBJECT OUTCOME IN CRITICALLY ILL SUBJECTS 审中-公开
标题翻译：作为主要观察指标的干扰素多态性
公开(公告)号：WO2007140625A1
公开(公告)日：2007-12-13
申请号：PCT/CA2007/001042
申请日：2007-06-11
申请人： THE UNIVERSITY OF BRITISH COLUMBIA , WALLEY, Keith, R. , RUSSELL, James, A. , WATTANATHUM, Anan
发明人： WALLEY, Keith, R. , RUSSELL, James, A. , WATTANATHUM, Anan
IPC分类号： C40B40/06 , A61K38/48 , A61P29/00 , C12Q1/68 , C40B40/14
CPC分类号： C12Q1/6883 , A61K38/4866 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156 , C12Q2600/172 , Y02A50/385 , Y02A50/401 , Y02A50/409 , Y02A50/411 , Y02A50/473 , Y02A50/478
摘要： The invention provides methods, nucleic acids, compositions and kits for predicting a subject's outcome with an inflammatory condition and a subject's response to treatment with activated protein C or protein C like compound to identify subjects having a greater benefit from treatment with activated protein C. The method generally comprises determining a interferon gamma (IFNG) gene polymorphism genotype(s) of a subject for one or more polymorphisms in the IFNG gene or associated sequence, comparing the determined genotype with known genotypes for the polymorphism that correspond with an improved response polymorphism to identify potential subjects having an inflammatory condition who are more likely to benefit from treatment with activated protein C or protein C like compound and subsequent to treatment recover from the inflammatory condition. The invention also provides for methods of treating such subjects with an anti-inflammatory agent or anti-coagulant agent based on the subject's genotype.
摘要翻译：本发明提供了用活性蛋白C或蛋白C类化合物治疗炎症状况和受试者对治疗反应的方法，核酸，组合物和试剂盒，用于预测受试者的结局，以鉴定用活化蛋白C治疗具有更大益处的受试者。方法通常包括确定受试者在IFNG基因或相关序列中的一个或多个多态性的干扰素γ（IFNG）基因多态性基因型，将确定的基因型与已知基因型与对应于改良的应答多态性的多态性进行比较，鉴定具有更有可能受到活化蛋白C或蛋白C类化合物治疗并随后治疗的炎症状况的潜在受试者从炎症状态恢复。本发明还提供了基于受试者的基因型用抗炎剂或抗凝血剂治疗这些受试者的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式